Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

   Active, not recruiting · Phase 4 · Prostate Cancer

   NCT05722925 · Blue Earth Diagnostics · 1 U.S. investigator

   $20,666research payments

2. 18F-FLUC PET/MR in Patients With Brain Mets

   Recruiting · Phase 3 · Brain Metastasis

   NCT06159335 · Blue Earth Diagnostics · 1 U.S. investigator

   $20,666research payments

3. EPI-743 for Mitochondrial Respiratory Chain Diseases

   No longer available · Mitochondrial Diseases

   NCT01370447 · Ptc Therapeutics, Inc. · 2 U.S. investigators

   $20,659research payments

4. INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

   Completed · Phase 4 · Diabetes Mellitus, Type 1

   NCT05904743 · Mannkind Corporation · 0 U.S. investigators

   $20,630research payments

5. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

   Recruiting · Schizophrenia

   NCT07101094 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $20,550research payments

6. Wound Healing Following Tooth Extraction and Ridge Preservation Using DFDBA Alone in Particulate Fiber Form and in Combination With Xenograft

   Completed · Not applicable · Dental Extraction

   NCT05400213 · Geistlich Pharma, North America, Inc. · 1 U.S. investigator

   $20,530research payments

7. A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

   Terminated · Phase 2, Phase 3 · Mitochondrial Diseases

   NCT04378075 · Ptc Therapeutics, Inc. · 2 U.S. investigators

   $20,215research payments

8. A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

   Completed · Phase 1, Phase 2 · Carcinoma, Non-Small-Cell Lung

   NCT02716116 · Takeda Pharmaceuticals U.S.A., Inc. · 4 U.S. investigators

   $20,002research payments

9. The MOTION Study - Treatment of LSS With the MILD Procedure

   Status unknown · Not applicable · Spinal Stenosis, Lumbar Region, With Neurogenic Claudication

   NCT03610737 · Stryker Corporation · 7 U.S. investigators

   $19,580research payments

10. Evaluation of ARi With OpSens SavvyWire

    Terminated · Aortic Valve Insufficiency

    NCT06295068 · Cardiva Medical, Inc. · 1 U.S. investigator

    $19,500research payments

11. A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

    Terminated · Phase 2 · Colitis Ulcerative

    NCT06867094 · Sanofi US Services Inc. · 0 U.S. investigators

    $19,496research payments

12. A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

    Withdrawn · Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF)

    NCT06019481 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $19,452research payments

13. A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

    Recruiting · Phase 3 · Epilepsy

    NCT04715646 · UCB SA · 1 U.S. investigator

    $19,443research payments

14. Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

    Completed · Phase 3 · Migraine

    NCT05861427 · AbbVie Inc. · 0 U.S. investigators

    $19,350research payments

15. Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment

    Active, not recruiting · Intracranial Aneurysm

    NCT04034810 · Balt USA, LLC · 0 U.S. investigators

    $19,325research payments

16. Trident II Tritanium Acetabular Shell Outcomes Study

    Terminated · Not applicable · Arthroplasty, Replacement, Hip

    NCT02999009 · Stryker Corporation · 5 U.S. investigators

    $19,083research payments

17. PHIL in the Treatment of Intracranial dAVF.

    Completed · Not applicable · Arteriovenous Dural Fistula

    NCT03467542 · Microvention, Inc. · 6 U.S. investigators

    $18,760research payments

18. A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

    Completed · Phase 3 · Paroxysmal Nocturnal Hemoglobinuria

    NCT05133531 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $18,732research payments

19. GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

    Active, not recruiting · Not applicable · Abdominal Aortic Aneurysm

    NCT06578741 · W. L. Gore & Associates, Inc. · 1 U.S. investigator

    $18,720research payments

20. Dupilumab in CRSsNP

    Completed · Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps

    NCT04678856 · Sanofi US Services Inc. · 1 U.S. investigator

    $18,403research payments

21. A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

    Active, not recruiting · Phase 3 · Carcinoma, Non-Small-Cell Lung

    NCT06140836 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $17,890research payments

22. An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT03844048 · AbbVie Inc. · 3 U.S. investigators

    $17,721research payments

23. Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Completed · Phase 2 · Chronic Lymphocytic Leukemia (CLL)

    NCT05105841 · AbbVie Inc. · 1 U.S. investigator

    $17,565research payments

24. A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06774313 · AbbVie Inc. · 0 U.S. investigators

    $17,552research payments

25. Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

    Terminated · Heart Failure

    NCT05860348 · Cvrx, Inc. · 5 U.S. investigators

    $17,527research payments

26. A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

    Active, not recruiting · Phase 3 · Metastatic Castration-resistant Prostate Cancer

    NCT06764485 · E.r. Squibb & Sons, L.l.c. · 0 U.S. investigators

    $17,510research payments

27. Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

    Active, not recruiting · Phase 1, Phase 2 · Locally Advanced Urothelial Carcinoma

    NCT03854474 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $17,500research payments

28. A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

    Completed · Phase 2 · Alzheimer's Disease

    NCT02880956 · AbbVie Inc. · 2 U.S. investigators

    $17,475research payments

29. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

    Completed · Phase 3 · Giant Cell Arteritis (GCA)

    NCT03725202 · AbbVie Inc. · 3 U.S. investigators

    $17,447research payments

30. Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

    Terminated · Phase 2 · Diffuse Cutaneous Systemic Sclerosis

    NCT04680975 · Sanofi US Services Inc. · 0 U.S. investigators

    $17,270research payments

31. A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

    Active, not recruiting · Phase 3 · Metastatic Colorectal Cancer

    NCT04008030 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $17,109research payments

32. Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

    Completed · Phase 3 · Asthma

    NCT02414854 · Genzyme Corporation · 0 U.S. investigators

    $17,000research payments

33. A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

    Recruiting · Phase 1 · Healthy Volunteers

    NCT07204418 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $16,981research payments

34. Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction

    Active, not recruiting · Not applicable · Heart Defects, Congenital

    NCT03441971 · W. L. Gore & Associates, Inc. · 0 U.S. investigators

    $16,830research payments

35. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

    Active, not recruiting · Phase 3 · Multiple Myeloma

    NCT03539744 · AbbVie Inc. · 4 U.S. investigators

    $16,807research payments

36. A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

    Active, not recruiting · Phase 3 · Breast Neoplasms

    NCT02107703 · Eli Lilly and Company · 2 U.S. investigators

    $16,776research payments

37. A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

    Recruiting · Phase 1 · Rheumatoid Arthritis (RA)

    NCT07258849 · Eli Lilly and Company · 1 U.S. investigator

    $16,685research payments

38. Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

    Recruiting · Phase 1, Phase 2 · Atrial Fibrillation, Postoperative

    NCT06730828 · Helios Cardio Inc · 1 U.S. investigator

    $16,250research payments

39. iCLAS™ for Persistent Atrial Fibrillation

    Completed · Not applicable · Persistent Atrial Fibrillation

    NCT04061603 · Adagio Medical, Inc. · 1 U.S. investigator

    $16,100research payments

40. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    Recruiting · Phase 2 · Multiple Sclerosis Spasticity

    NCT06782490 · E.r. Squibb & Sons, L.l.c. · 10 U.S. investigators

    $16,072research payments

41. A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

    Completed · Phase 4 · Upper Facial Lines

    NCT06218251 · AbbVie Inc. · 11 U.S. investigators

    $15,839research payments

42. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    Recruiting · Phase 3 · Non-small Cell Lung Cancer

    NCT06561386 · E.r. Squibb & Sons, L.l.c. · 9 U.S. investigators

    $15,738research payments

43. Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

    Recruiting · Coronary Artery Disease

    NCT05491668 · Cardiva Medical, Inc. · 2 U.S. investigators

    $15,618research payments

44. Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

    Terminated · Phase 3 · Congenital Cystic Kidney Disease

    NCT04705051 · Genzyme Corporation · 1 U.S. investigator

    $15,600research payments

45. Diffuse Optical Monitoring With Inhaled Nitric Oxide

    Active, not recruiting · Phase 2 · Stroke

    NCT03023449 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

    $15,525research payments

46. A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

    Terminated · Phase 1 · Healthy

    NCT06119529 · Eli Lilly and Company · 1 U.S. investigator

    $15,468research payments

47. Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

    Recruiting · IGF1 Deficiency

    NCT00903110 · Ipsen Pharma Sas · 2 U.S. investigators

    $15,407research payments

48. Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

    Recruiting · Phase 3 · Alopecia Areata

    NCT07133308 · Sun Pharmaceutical Industries Inc. · 1 U.S. investigator

    $15,250research payments

49. The ArtixASCEND Study

    Recruiting · Not applicable · Acute Lower Limb Arterial Occlusion

    NCT07135895 · Stryker Corporation · 1 U.S. investigator

    $15,100research payments

50. Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

    Completed · Paroxysmal Atrial Fibrillation

    NCT03729830 · Boston Scientific Corporation · 6 U.S. investigators

    $15,090research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.